Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Irbesartan

FDA-approved product (tablet, oral), marketed as Avapro, Irbesartan.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Irbesartan
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Cardiovascular disease
  • Chronic kidney disease
  • Chronic renal failure syndrome
  • Diabetic nephropathy
  • Hypertension
  • Type 2 diabetes mellitus

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Angiotensin ii receptor blockers (arbs), plain
FDA pharmacologic class
Angiotensin 2 Receptor Blocker FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against E. coli, MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA57.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli49.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae21.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis59.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Irbesartan in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-8.1 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.8 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.5 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-8.4 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Irbesartan with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Irbesartan in Heart Failure With Preserved Systolic Function (I-Preserve)

    NCT00095238 · start 2002-06

    Registered record
    Registry ID
    NCT00095238
    Conditions
    Congestive Heart Failure
    Interventions
    Irbesartan; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2002-06
    Completion
    2008-07
    Enrolment
    4,128

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCongestive Heart Failure
    InterventionIrbesartan; Placebo
    PhasePhase 3
    Registry statusCompleted

  • Using the Drug Spironolactone to Test If It Reduces Protein Leakage From the Kidney

    NCT00106561 · start 2002-01

    Registered record
    Registry ID
    NCT00106561
    Conditions
    Kidney Disease; Diabetic Nephropathy; Glomerulonephritis; Proteinuria
    Interventions
    Spironolactone; Irbesartan
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Completed
    Start
    2002-01
    Completion
    2004-09
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionKidney Disease; Diabetic Nephropathy; Glomerulonephritis; Proteinuria
    InterventionSpironolactone; Irbesartan
    PhasePhase 2 / Phase 3
    Registry statusCompleted

  • Characterization of Vascular Effects of Angiotensin II in Dorsal Human Hand Veins.

    NCT00180024 · start 2002-01

    Registered record
    Registry ID
    NCT00180024
    Conditions
    Healthy Subjects
    Interventions
    irbesartan (drug)
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2002-01
    Completion
    2005-09
    Enrolment
    Not recorded

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Subjects
    Interventionirbesartan (drug)
    PhaseNot applicable
    Registry statusCompleted

  • Diabetes Risk Evaluation and Microalbuminuria in Saskatchewan First Nations Peoples

    NCT00741702 · start 2001-09

    Registered record
    Registry ID
    NCT00741702
    Conditions
    Hypertension; Diabetes Mellitus
    Interventions
    Nurse administered treatment algorithm
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2001-09
    Completion
    2003-03
    Enrolment
    95

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertension; Diabetes Mellitus
    InterventionNurse administered treatment algorithm
    PhaseNot applicable
    Registry statusCompleted

  • Irbesartan in Type 2 Diabetes

    NCT00317915

    Registered record
    Registry ID
    NCT00317915
    Conditions
    Type 2 Diabetes; Microalbuminuria; Hypertension
    Interventions
    Irbesartan treatment
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    Not recorded
    Completion
    Not recorded
    Enrolment
    Not recorded

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionType 2 Diabetes; Microalbuminuria; Hypertension
    InterventionIrbesartan treatment
    PhasePhase 3
    Registry statusCompleted